Skip to main content
    S

    Sellas Life Sciences Group Inc (SLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.47
    -0.39 (-4.96%)

    Market Cap: $1.60B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sellas Life Sciences Group Inc (SLS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Sellas Life Sciences Group are Celldex Therapeutics (CLDX), Maravai Lifesciences Holdings (MRVI) and Structure Therapeutics Inc. American Depositary Shares (GPCR). By market cap, Sellas Life Sciences Group ranks 6th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.

    Peer Comparison

    SLS's revenue growth of -82.5% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Sellas Life Sciences Group (SLS)$1.60BN/AN/A0.0%N/A-82.5%0.00%
    Celldex Therapeutics Inc (CLDX)$2.26BN/AN/A0.0%N/A-97.0%0.00%
    Maravai Lifesciences Holdings Inc (MRVI)$1.96BN/A5.2x-30.8%-28.3%10.1%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Silence Therapeutics PLC (SLN)$1.23BN/A882.5x0.0%N/A197.2%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Intellia Therapeutics Inc (NTLA)$1.36BN/A26.1x0.0%-50.0%-48.0%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Vor Biopharma Inc (VOR)$1.19BN/AN/A0.0%N/A0.0%0.00%
    Tyra Biosciences Inc (TYRA)$1.38BN/AN/A0.0%N/A0.0%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Zenas BioPharma, Inc. Common Stock (ZBIO)$1.90BN/A168.0x0.0%-104.3%-100.0%0.00%
    Peer median$1.42B14.2x10.8x0.0%-28.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Sellas Life Sciences Group, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Celldex Therapeutics Inc (CLDX)
    Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment...
    CLDX competitors
    Maravai Lifesciences Holdings Inc (MRVI)
    Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines...
    MRVI competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Silence Therapeutics PLC (SLN)
    Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology...
    SLN competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Intellia Therapeutics Inc (NTLA)
    Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
    NTLA competitors
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Vor Biopharma Inc (VOR)
    Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients.
    VOR competitors
    Tyra Biosciences Inc (TYRA)
    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes...
    TYRA competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Zenas BioPharma, Inc. Common Stock (ZBIO)
    Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based...
    ZBIO competitors

    Frequently Asked Questions About SLS

    Who are Sellas Life Sciences Group's main competitors?

    The companies most similar to Sellas Life Sciences Group include Celldex Therapeutics (CLDX), Maravai Lifesciences Holdings (MRVI), Structure Therapeutics Inc. American Depositary Shares (GPCR), Silence Therapeutics (SLN) and Nuvation Bio (NUVB), listed from the closest match.

    Who is Sellas Life Sciences Group's biggest competitor?

    Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Celldex Therapeutics (CLDX) is the closest match by business profile, size, sector and industry.

    How does SLS stock compare with its competitors?

    SLS' net margin is 0.0% against a peer median of 0.0%.

    Which of Sellas Life Sciences Group's competitors pays a higher dividend?

    Sellas Life Sciences Group pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Sellas Life Sciences Group bigger than its competitors?

    No. Sellas Life Sciences Group is 6th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.